Symptomtext
received a dose of MENACTRA instead of the MMR vaccine with no reported adverse event; Initial information received on 16-Nov-2021 regarding an unsolicited valid non-serious case from an other health professional via Media Information (under the reference 00860685). This case involves a 12 months old male patient who received a dose of MENINGOCOCCAL A-C-Y-W135 (D CONJ) VACCINE [MENACTRA] instead of the MMR VACCIN (wrong product administered). The patient's medical history, past medical treatment(s), vaccination(s) and family history were not provided. Concomitant medications included PNEUMOCOCCAL VACCINE CONJ 13V (CRM197) (PREVNAR 13); VARICELLA ZOSTER VACCINE (VARICELLA VACCINE) and HIB VACCINE CONJ (TET TOX) (ACT-HIB) (lot number and expiration date not reported) via unknown route in an unknown administration site for Prophylactic vaccination. On 15-Nov-2021, the patient received a dose of suspect MENACTRA (0.5 ml, total, once, lot U7140BB and expiration date: 7-Nov-2022) via intramuscular route in the right thigh for Prophylactic vaccination. It was an actual medication error due to wrong product administered (same day latency). No adverse event was reported. It was reported "A 12 month and 9 day old patient received a dose of MENACTRA instead of the measles, mumps, and rubella (MMR vaccine) at their visit on 15Nov2021. Caller stated the patient was mistakenly administered the MENACTRA vaccine and was not sure what to do. Caller did state that the patient has not received any other prior dose of MENACTRA. Caller mentioned that her clinic only administers MENACTRA to patients older than 11 years of age. Agent did inform caller that MENACTRA is approved for ages 9 months to 55 years of age, and that primary vaccination in children 9 through 23 months of age is 2 doses 3 months apart. Caller was provided with the normal adverse effects of MENACTRA on children 9 through 12 months of age." This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.